HORSHAM, Pa.--(BUSINESS WIRE)--ImpactRx, a Symphony Technology Group (STG) company, and the pioneer in measuring the impact of promotion on physicians’ attitudes and prescribing behavior, announced today that it has acquired AlphaDetail, Inc., a leader in global healthcare primary market research and influence network mapping. AlphaDetail was recently named one of the top fifty US market research firms in the annual Honomichl survey. Financial terms of the transaction were not disclosed.
AlphaDetail will be closely integrated across ImpactRx’s operations, but will maintain its name and branding and will operate as the custom market research unit of the company. AlphaDetail’s existing management team will continue to lead the unit and Rishi Varma, AlphaDetail’s current CEO, will also become Executive Vice President, Custom Market Research, ImpactRx and will report to ImpactRx President and CEO, Gregory Ellis.
“We are very excited to add AlphaDetail’s custom research expertise and consultative approach to ImpactRx’s broad portfolio of promotional effectiveness and consulting analytics solutions,” declared Ellis. “AlphaDetail’s deep understanding of client needs and exceptional analytical talent will enable ImpactRx to provide incremental value to our clients,” Ellis stated. “For example, clients’ product forecasting needs will be better served by integrating AlphaDetail’s trusted ability to develop and conduct actionable research with ImpactRx’s data assets and capabilities,” concluded Ellis.
“We are thrilled to join ImpactRx at this stage in the company’s development,” said Rishi Varma, AlphaDetail’s CEO. “Since AlphaDetail’s inception eleven years ago, we have focused on building our business through an unparalleled commitment to our clients and to execution excellence,” Varma continued. “We’re eager to begin integrating this focus and our skill set with ImpactRx’s unique research model and world-class data and analytical assets to deliver even more value to our combined customer base,” concluded Varma.
“Our strategic intent when we acquired ImpactRx almost one year ago was to build a differentiated solutions company in life sciences capable of delivering compelling value through insights informed by data,” said J.T. Treadwell, Managing Director with STG. “AlphaDetail is a great organization with a reputation for quality work and highly satisfied customers, as is ImpactRx. The addition of AlphaDetail’s strong global custom research expertise, analytical skill and therapeutic knowledge to ImpactRx’s innovative and extensive promotional effectiveness capabilities will enable us to significantly broaden our footprint as a best-in-class solutions provider,” Treadwell stated.
About ImpactRx
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry. Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace. Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions. The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients. These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning. ImpactRx is a Symphony Technology Group company (www.symphonytg.com) and AlphaDetail (www.alphadetail.com) is ImpactRx’s global custom market research unit. For more information, visit: www.impactrx.com.
About Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. In addition to capital, STG provides transformation expertise to enable its portfolio companies to deliver maximum value to clients, to retain and attract the best talent, to drive growth through innovation, and to achieve best-in-class business performance. STG's current portfolio consists of fourteen global companies with combined revenue of $2.5 billion and 15,000 employees spread across North America, Europe and Asia. For more information, visit: www.symphonytg.com.